Price loading...

CRC Press Biosimilar and Interchangeable Biologics: From Cell Line to Commercial Launch, Two Volume Set

Price data last checked 102 day(s) ago - refreshing...

View at Amazon

Price History & Forecast

No Price Data Available

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

What’s the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch covers the strategic and tactical elements of biosimilars in two volumes. The first volume, Biosimilars and Interchangeable Biologics: Strategic Elements, explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets. This volume also examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. The second volume, Biosimilars and Interchangeable Biologics: Tactical Elements, explores the development and manufacturing of biosimilars and targets challenges surrounding the creation of these products. This includes manufacturing, production costs, and intellectual property barriers, particularly in regulated markets (regulatory agencies are still in the process of developing guidelines). It addresses the complexity of biological drugs, and it discusses specific structural elements vital to the functionality, immunogenicity, and safety of biosimilar products. This volume also provides an overall understanding of the hurdles, difficulties, and practicalities of developing a strong plan. It introduces a step-by-step approach for creating a strategy that helps develop and manufacture a biosimilar product while reducing overall production costs and meeting the requirements of biosimilarity based on analytical and functional, pharmacokinetic, pharmacodynamic (where applicable), and nonclinical toxicology or toxicokinetic similarity (where appropriate) while remaining competitive in the market. Thus, Biosimilars and Interchangeable Biologics: From Cell Line to Commercial Launch, Two-Volume Set supplies practitioners, researchers, and scientists in the biopharmaceutical industry with a valuable resource for practical information at all stages of the biosimilar product process.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
07 January 2016
Listed Since
02 June 2015

Barcode

No barcode data available

Similar Products You Might Like

Biosimilars and Interchangeable Biologics: Strategic Elements
97% match

Biosimilars and Interchangeable Biologics: Strategic Elements

CRC Press

£230.60 11 Feb 2026
Biosimilars and Interchangeable Biologics: Tactical Elements
97% match

Biosimilars and Interchangeable Biologics: Tactical Elements

CRC Press

£171.39 16 Feb 2026
Biosimilars and Interchangeable Biologics: Tactical Elements
97% match

Biosimilars and Interchangeable Biologics: Tactical Elements

CRC Press

£49.99 28 Feb 2026
Biologics and Biosimilars: Drug Discovery and Clinical Applications
96% match

Biologics and Biosimilars: Drug Discovery and Clinical Applications

CRC Press

£45.07 07 Feb 2026
Biosimilars Development Strategies: Fast to Market Approaches
95% match

Biosimilars Development Strategies: Fast to Market Approaches

CRC Press

£106.72 22 Jan 2026
Biosimilars and Interchangeable Biologics: Strategic Elements
95% match

Biosimilars and Interchangeable Biologics: Strategic Elements

CRC Press

£27.37 08 Mar 2026
Biopharmaceuticals: Challenges and Opportunities
94% match

Biopharmaceuticals: Challenges and Opportunities

CRC Press

£125.90 08 Jan 2026
Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics Series)
94% match

Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics Series)

CRC Press

£95.60 08 Mar 2026
Methodologies in Biosimilar Product Development (Chapman & Hall/CRC Biostatistics Series)
94% match

Methodologies in Biosimilar Product Development (Chapman & Hall/CRC Biostatistics Series)

CRC Press

£129.36 13 Apr 2026
Wiley - Biological Drug Products: Development and Strategies
94% match

Wiley - Biological Drug Products: Development and Strategies

Wiley

£127.69 26 Feb 2026
Handbook of Bioequivalence Testing (Drugs and the Pharmaceutical Sciences)
94% match

Handbook of Bioequivalence Testing (Drugs and the Pharmaceutical Sciences)

CRC Press

£43.14 09 Feb 2026
Nonclinical Development of Novel Biologics, Biosimilars and Specialty Biologics
94% match

Nonclinical Development of Novel Biologics, Biosimilars and Specialty Biologics

Academic Press

£105.79 17 Feb 2026
Developability of Biotherapeutics: Computational Approaches
93% match

Developability of Biotherapeutics: Computational Approaches

CRC Press

£107.48 09 Mar 2026
Multiregional Clinical Trials for Simultaneous Global New Drug Development (Chapman & Hall/CRC Biostatistics Series)
93% match

Multiregional Clinical Trials for Simultaneous Global New Drug Development (Chapman & Hall/CRC Biostatistics Series)

CRC Press

£49.34 07 Mar 2026
Current Applications of Pharmaceutical Biotechnology: 171 (Advances in Biochemical Engineering/Biotechnology, 171)
93% match

Current Applications of Pharmaceutical Biotechnology: 171 (Advances in Biochemical Engineering/Biotechnology, 171)

£271.91 08 Jan 2026
Development of Biopharmaceutical Drug-Device Products: 35 (AAPS Advances in the Pharmaceutical Sciences Series, 35)
93% match

Development of Biopharmaceutical Drug-Device Products: 35 (AAPS Advances in the Pharmaceutical Sciences Series, 35)

£179.10 13 Jan 2026
Academic Press Biotherapeutics Formulation and Device Management
93% match

Academic Press Biotherapeutics Formulation and Device Management

Academic Press

£131.39 18 Apr 2026
Current Applications of Pharmaceutical Biotechnology: 171 (Advances in Biochemical Engineering/Biotechnology, 171)
93% match

Current Applications of Pharmaceutical Biotechnology: 171 (Advances in Biochemical Engineering/Biotechnology, 171)

Springer

£240.00 13 Jan 2026
Development of Biopharmaceutical Drug-Device Products: 35 (AAPS Advances in the Pharmaceutical Sciences Series, 35)
93% match

Development of Biopharmaceutical Drug-Device Products: 35 (AAPS Advances in the Pharmaceutical Sciences Series, 35)

Springer

£160.00 13 Jan 2026
Commercialization of BioPharma Products in the USA (BW): A Practical Guide
93% match

Commercialization of BioPharma Products in the USA (BW): A Practical Guide

Rxcommercial Research International, Incorporated

£160.70 14 Feb 2026
Analytical Similarity Assessment in Biosimilar Product Development
93% match

Analytical Similarity Assessment in Biosimilar Product Development

CRC Press

£161.72 10 Mar 2026
Patient-Focused Network Integration in BioPharma: Strategic Imperatives for the Years Ahead
93% match

Patient-Focused Network Integration in BioPharma: Strategic Imperatives for the Years Ahead

CRC Press

£48.42 20 Feb 2026
Handbook of Cell and Gene Therapy: From Proof-of-Concept through Manufacturing to Commercialization
93% match

Handbook of Cell and Gene Therapy: From Proof-of-Concept through Manufacturing to Commercialization

£43.23 08 Jan 2026
Springer Competitive Strategies in Life Sciences: 1 (Book)
93% match

Springer Competitive Strategies in Life Sciences: 1 (Book)

Springer

£108.97 01 Mar 2026